Steven M. Dubinett, MD, on Early Lung Cancer Development and Testing Methods

Stand Up To Cancer’s (SU2C’s) SU2C–LUNGevity Foundation–American Lung Association (ALA) Lung Cancer Interception Dream Team is currently trying to understand how early lung cancer develops and is testing methods to block this development using several complementary approaches.

Utilizing human lung cancer tissue, the team of medical experts have developed laboratory models to understand the inflammatory process in the lung’s bronchial cells, and how that relates to early lung cancer development. Importantly, this research has the potential to yield benefits in other areas, such as the coronavirus disease 2019 (COVID-19).

Additionally, the researchers are developing 2 sets of diagnostic tools that will be able to detect lung cancer early. The first set involves using nasal swabs and imaging to determine whether lung abnormalities found in chest images are lung cancer or benign lung characteristics. The second involves the use of blood tests to identify patients at the earliest stages of lung cancer recurrence.

In an interview with CancerNetwork®, Steven M. Dubinett, MD, co-leader of the Dream Team from the University of California, Los Angeles, discussed this research further and what he hopes it will provide for patients with lung cancer.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Reference:

SU2C. SU2C–LUNGEVITY FOUNDATION–AMERICAN LUNG ASSOCIATION LUNG CANCER INTERCEPTION DREAM TEAM: INTERCEPT LUNG CANCER THROUGH IMMUNE, IMAGING, AND MOLECULAR EVALUATION (INTIME). SU2C website. Published 2020. Accessed November 19, 2020. https://standuptocancer.org/research/research-portfolio/dream-teams/lung-cancer-interception-intime-dream-team/